Loss of miR-101-3p Promotes Transmigration of Metastatic Breast Cancer Cells through the Brain Endothelium by Inducing COX-2/MMP1 Signaling.

blood–brain barrier brain metastasis breast cancer micro-RNA

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
07 Jul 2020
Historique:
received: 01 07 2020
revised: 03 07 2020
accepted: 06 07 2020
entrez: 11 7 2020
pubmed: 11 7 2020
medline: 11 7 2020
Statut: epublish

Résumé

Brain metastases represent one of the incurable end stages in breast cancer (BC). Developing effective or preventive treatments is hampered by a lack of knowledge on the molecular mechanisms driving brain metastasis. Transmigration of BC cells through the brain endothelium is a key event in the pathogenesis of brain metastasis. In this study, we identified miR-101-3p as a critical micro-RNA able to reduce transmigration of BC cells through the brain endothelium. Our results revealed that miR-101-3p expression is downregulated in brain metastatic BC cells compared to less invasive variants, and varies inversely compared to the brain metastatic propensity of BC cells. Using a loss-and-gain of function approach, we found that miR-101-3p downregulation increased transmigration of BC cells through the brain endothelium in vitro by inducing COX-2 expression in cancer cells, whereas ectopic restoration of miR-101-3p exerted a metastasis-reducing effect. In regulatory experiments, we found that miR-101-3p mediated its effect by modulating COX-2-MMP1 signaling capable of degrading the inter-endothelial junctions (claudin-5 and VE-cadherin), key components of the brain endothelium. These findings suggest that miR-101-3p plays a critical role in the transmigration of breast cancer cells through the brain endothelium by modulating the COX-2-MMP1 signaling and thus may serve as a therapeutic target that can be exploited to prevent or suppress brain metastasis in human breast cancer.

Identifiants

pubmed: 32645833
pii: ph13070144
doi: 10.3390/ph13070144
pmc: PMC7407639
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Terry Fox Foundation
ID : I1032
Organisme : The University of Sharjah
ID : The University of Sharjah competitive grant (No. 180111030)

Références

Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
FEBS J. 2012 Nov;279(22):4201-12
pubmed: 23013439
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):132-147
pubmed: 28341420
Mol Med Rep. 2014 Mar;9(3):779-85
pubmed: 24366267
Oncogene. 2012 May 17;31(20):2499-511
pubmed: 21963843
Mol Cell Biol. 2004 Oct;24(19):8408-17
pubmed: 15367662
Anticancer Res. 2011 Dec;31(12):4307-13
pubmed: 22199296
Drug Des Devel Ther. 2015 Feb 18;9:1103-75
pubmed: 25733820
J Neurosci. 2013 Apr 3;33(14):5992-6000
pubmed: 23554480
PLoS One. 2015 Nov 10;10(11):e0140642
pubmed: 26556718
Cancer Cell Int. 2012 Dec 19;12(1):53
pubmed: 23249419
Cancer Prev Res (Phila). 2011 Jul;4(7):1073-83
pubmed: 21430074
Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):245-58
pubmed: 27365375
Methods Mol Biol. 2011;762:333-45
pubmed: 21717368
Oncogene. 2015 Sep 10;34(37):4890-900
pubmed: 25659578
Nat Biotechnol. 2013 Jul;31(7):577
pubmed: 23839128
Med Sci Monit. 2017 Apr 18;23:1857-1871
pubmed: 28416776
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15144-9
pubmed: 17848513
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Cell Physiol Biochem. 2014;34(2):413-22
pubmed: 25059472
Cancer Med. 2018 Aug;7(8):3820-3833
pubmed: 29992751
Neuro Oncol. 2018 Oct 9;20(11):1439-1449
pubmed: 29566179
Front Biosci (Schol Ed). 2016 Jan 01;8:187-202
pubmed: 26709907
Int J Mol Sci. 2014 Jun 11;15(6):10508-26
pubmed: 24921708
Nat Rev Clin Oncol. 2011 Jun;8(6):344-56
pubmed: 21487419
Front Biosci (Elite Ed). 2016 Jan 01;8:245-63
pubmed: 26709660
Exp Cell Res. 2009 May 1;315(8):1439-47
pubmed: 19133256
Nat Rev Clin Oncol. 2019 Mar;16(3):185-204
pubmed: 30514977
Int J Mol Sci. 2016 Dec 09;17(12):
pubmed: 27941681
Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412
pubmed: 25561720
J Biol Chem. 2015 Apr 10;290(15):9842-54
pubmed: 25691572
Trends Cancer. 2018 Mar;4(3):176-196
pubmed: 29506669
Nature. 2011 Dec 14;481(7380):190-4
pubmed: 22170610
Cancer Lett. 2016 Dec 1;383(1):18-27
pubmed: 27693460
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Cancer Genomics Proteomics. 2015 Jul-Aug;12(4):167-77
pubmed: 26136217
Nat Biotechnol. 2008 Apr;26(4):462-9
pubmed: 18362881
Oncotarget. 2015 Oct 13;6(31):30818-30
pubmed: 26360780
Cancer Cell. 2015 Feb 9;27(2):163-75
pubmed: 25670078
Curr Neuropharmacol. 2018;16(9):1375-1384
pubmed: 29473514
Breast. 2014 Oct;23(5):623-8
pubmed: 24993072
Cancer Res. 2011 Feb 1;71(3):645-54
pubmed: 21266359
Nature. 2009 Jun 18;459(7249):1005-9
pubmed: 19421193
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
J Hepatol. 2015 Feb;62(2):448-57
pubmed: 25308172
Am J Transl Res. 2017 May 15;9(5):2088-2105
pubmed: 28559963
Nature. 2008 Jan 10;451(7175):147-52
pubmed: 18185580
PLoS One. 2012;7(10):e46173
pubmed: 23071542
Nat Commun. 2015 Apr 01;6:6716
pubmed: 25828099
Int J Mol Sci. 2013 Jan 11;14(1):1383-411
pubmed: 23344048
J Bone Miner Res. 2001 Aug;16(8):1486-95
pubmed: 11499871
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
Oncol Lett. 2016 Oct;12(4):2538-2544
pubmed: 27698824

Auteurs

Rania Harati (R)

Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, UAE.
Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O. Box 27272, UAE.

Mohammad G Mohammad (MG)

Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O. Box 27272, UAE.
Department of Medical Laboratories, College of Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, UAE.

Abdelaziz Tlili (A)

Department of Applied Biology, College of Sciences, University of Sharjah, Sharjah P.O. Box 27272, UAE.

Raafat A El-Awady (RA)

Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, UAE.
Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O. Box 27272, UAE.

Rifat Hamoudi (R)

Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O. Box 27272, UAE.
Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, UAE.

Classifications MeSH